You are here
Muscle Invasive Bladder Cancer (MIBC)
This section considers studies on:
- New systemic therapies for muscle invasive bladder cancer (metastatic or complementary therapies to cystectomy)
- The role of lymphadenectomy in muscle invasive bladder cancer
- Indications for bladder preservation in muscle invasive bladder cancer
- Role of metastatectomy on muscle invasive bladder cancer
- New techniques for cystectomy
Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, et al.04/19/2017
Editorial comment from Piotr Chlosta:
In clinical practice, BPT patients have similar survival to RC patients when treated with curative radiotherapy doses. Choice of concurrent chemotherapy regimen varied widely with no clear standard.
R. Seiler, B. Winters, J. Douglas, B. van Rhijn, G. Sjödahl, S. Lerner, et al.03/30/2017
Editorial comment from Prof. Piotr Chlosta:
Benefit of cisplatin based neoadjuvant chemotherapy varied depending on molecular subtype of bladder cancer. NAC (compared to surgery alone) was associated with improvement in prognosis in basal subtype, while there was no improvement for other subtypes. Results suggest that molecular subtyping may help in selecting patients who could benefit most from NAC, and patients who could be best managed with surgery alone.
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, et al.02/01/2017
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
J Clin Oncol. 2014 Jun 20;32(18):1895-901.02/17/2015
BJU Int. 2014 Nov;114(5):719-2602/06/2015
EAU 2017 Scientific Programme and Sessions
View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.